Australia markets closed

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
41.87-0.74 (-1.74%)
At close: 04:00PM EDT
41.26 -0.61 (-1.46%)
After hours: 04:05PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 3.54B
Enterprise value 3.17B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.42
Price/book (mrq)25.25
Enterprise value/revenue 7.16
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.68
52-week change 3-17.43%
S&P500 52-week change 326.49%
52-week high 354.98
52-week low 331.52
50-day moving average 345.26
200-day moving average 342.06

Share statistics

Avg vol (3-month) 3733.42k
Avg vol (10-day) 3734.19k
Shares outstanding 583.13M
Implied shares outstanding 683.13M
Float 873.21M
% held by insiders 14.02%
% held by institutions 198.94%
Shares short (30 Apr 2024) 44.65M
Short ratio (30 Apr 2024) 46.44
Short % of float (30 Apr 2024) 46.52%
Short % of shares outstanding (30 Apr 2024) 45.59%
Shares short (prior month 28 Mar 2024) 43.92M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -138.58%
Operating margin (ttm)-151.93%

Management effectiveness

Return on assets (ttm)-26.97%
Return on equity (ttm)-340.05%

Income statement

Revenue (ttm)442.59M
Revenue per share (ttm)5.75
Quarterly revenue growth (yoy)8.30%
Gross profit (ttm)N/A
EBITDA -550.84M
Net income avi to common (ttm)-613.35M
Diluted EPS (ttm)-7.95
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)412.08M
Total cash per share (mrq)4.96
Total debt (mrq)932.17M
Total debt/equity (mrq)664.59%
Current ratio (mrq)2.43
Book value per share (mrq)1.69

Cash flow statement

Operating cash flow (ttm)-508.67M
Levered free cash flow (ttm)-329.48M